OnKure Therapeutics (NASDAQ:OKUR) Price Target Cut to $34.00 by Analysts at HC Wainwright

OnKure Therapeutics (NASDAQ:OKUR) had its target price decreased by research analysts at HC Wainwright from $40.00 to $34.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other brokerages have also issued reports on OKUR. Leerink Partners assumed coverage on OnKure Therapeutics in a research note on Thursday, December 5th. They issued an “outperform” rating and a $33.00 target price for the company. Oppenheimer cut their price objective on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research note on Tuesday, March 11th. Finally, Leerink Partnrs upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, OnKure Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $32.33.

OnKure Therapeutics Stock Performance

OnKure Therapeutics stock opened at $4.82 on Tuesday. OnKure Therapeutics has a fifty-two week low of $4.45 and a fifty-two week high of $20.00. The stock has a market cap of $64.76 million, a PE ratio of -0.40 and a beta of 0.28. The firm’s fifty day moving average is $5.66.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings results on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51). On average, equities research analysts forecast that OnKure Therapeutics will post -4.05 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Acorn Capital Advisors LLC purchased a new stake in OnKure Therapeutics during the 4th quarter valued at $12,381,000. Citadel Advisors LLC bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at about $8,782,000. Samsara BioCapital LLC purchased a new stake in shares of OnKure Therapeutics during the fourth quarter worth about $7,088,000. Vestal Point Capital LP bought a new stake in shares of OnKure Therapeutics in the fourth quarter worth about $5,461,000. Finally, Deep Track Capital LP purchased a new position in OnKure Therapeutics during the 4th quarter valued at about $4,506,000. Institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.